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Available online 14 November 2016Treatment of neuropathic pain remains challenging as the etiology is heterogeneous and pathomechanisms are
incompletely understood. One possible mechanism is oxidative stress due to unphysiological reactive oxygen
species (ROS) formation. The only know dedicated enzymatic source of ROS are NADPH oxidases of which the
type 4 isoform (NOX4) has been suggested to be involved in the subacute and chronic phase of neuropathic
pain. Here, we aim to translate this finding into a treatment strategy by examining the efficacy of the NOX1/4-
specific inhibitor GKT136901 using the chronic constriction injury (CCI) mouse model of neuropathic pain. Un-
expectedly, post-nerve lesion treatment using GKT136901 was ineffective to reduce pain-related behavior
after CCI. We therefore re-investigated the role of NOX4 using an independent KO mouse model. Early after
CCI we found an increase in pro-inflammatory cytokines, ROS formation and the oxidative stress marker
nitrotyrosine in the lesioned nerve together with an upregulated Nox4 gene expression. In NOX4 KO mice, me-
chanical allodynia was markedly reduced from day 4 after nerve injury as were all ROS related and acute bio-
markers. In addition, we observed a reduction in the CCI-induced upregulation of pro-inflammatory cytokines
in the sciatic nerve and dorsal root ganglia alongwith NOX4-deficiency. Thus, we conclude that NOX4 is involved
in the development of neuropathic pain states by producing oxidative stress and subsequent cytokine dysregu-
lation at the lesion site. This appears at very early stages immediately after nerve injury explaining ineffectiveness
of post-acute pharmacological NOX inhibition. We suggest that future target validation of NOX4 should now
focus on defining the possible therapeutic window in human neuropathic pain.





Neuropathic pain is a major public health problem that affects ap-
proximately 6%of the adult populationworldwide. Despite several ther-
apeutic options, treatment of neuropathic pain remains challenging
because of the heterogeneous etiology and the multifactorial mecha-
nisms underlying this disease (Finnerup et al., 2015). Nerve damage in-
duces a complexmachinery of pathophysiologic events in the periphery
including neuronal hyperexcitability, changes in perineuronal homeo-
stasis, altered gene expression, and the induction of a strong immune
response (Rotshenker, 2011). Thesemechanisms together with second-
ary events in the central pain processing pathways contribute to the de-
velopment and maintenance of a steady-state pain condition.
Several studies have indicated that oxidative stress induced by an
imbalance in redox homeostasis is critically involved in the inductionl, Hans Berger Department of
is).of neuropathic pain (Jaggi and Singh, 2011; Kallenborn-Gerhardt et al.,
2013; Salvemini et al., 2011). Oxidative stress occurs due to overproduc-
tion of free radicals, i.e. reactive oxygen species (ROS) such as superox-
ide anion (O2−) or hydrogen peroxide (H2O2) together with a failure of
antioxidant defense mechanisms (Altenhöfer et al., 2012). Intracellular
accumulation of ROS and disturbances in the cellular redox state are
the consequences that then induce not only to general oxidative stress
responses like DNA fragmentation, breakdown of signaling pathways,
and tissue damage, but also neuronal degeneration and sensitization
in pain conditions (Salvemini et al., 2011; Schafer and Buettner, 2001).
Accordingly, therapeutically balancing of ROS by the administration of
antioxidants or free radical scavengers appears encouraging, but to
date, efforts to inhibit ROS have not yielded beneficial effects in pain
conditions (Kallenborn-Gerhardt et al., 2013; Schwartz et al., 2008;
Steinhubl, 2008; Yowtak et al., 2013). Prevention of ROS generation,
rather than scavenging already formed free radicals, represents another
possibility to target oxidative stress (Altenhofer et al., 2014; Padi and
Kulkarni, 2008).
One source of ROS production is the enzyme family of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases (NOX). Compared
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their primary function (Altenhofer et al., 2014; Opitz et al., 2007). The
rodent genome encodes four genes that contain the catalytic NOX sub-
unit, namely Nox1, Nox2, Nox3, and Nox4 (Altenhöfer et al., 2012). This
electron-transferring subunit is constitutively inactive in resting cells
and generates ROS only upon activation, e.g. after noxious stimuli
(Salvemini et al., 2011). While NOX2 activation is predominantly asso-
ciated with innate immunity mediated host defense (Lam et al., 2010)
and NOX1 with blood pressure control and related vascular mecha-
nisms (Gavazzi et al., 2006), NOX4 was shown highly expressed under
ischemic conditions in the central nervous system, e.g. ischemic stroke
(Kleinschnitz et al., 2010; Suzuki et al., 2012).
Recent evidence identified activation of NOX as a causative factor
that contributes to inflammatory or neuropathic pain role in the periph-
eral nervous system (Ibi et al., 2008; Kallenborn-Gerhardt et al., 2012,
2014; Kim et al., 2010). Interestingly, NOX4 was reported to be impor-
tant in the subacute and late-phase of neuropathic pain but to be dis-
pensable for basal sensitivity and for inflammatory pain conditions as
evaluated in a NOX4 KO mouse model (Kallenborn-Gerhardt et al.,
2012). Injury-induced ROS production as well as subsequent
dysmyelination processes of peripheral nerves were identified as the
potential underlying mechanisms. Tamoxifen-induced Nox4 gene dele-
tionwas effective in reducingpain behavior in late stages of neuropathic
pain. Here, we first aimed to evaluate the effect of a pharmacological
NOX4 blockade using the NOX1/4 inhibitor GKT136901 in the chronic
constriction injury (CCI) mouse model of neuropathic pain. Since post-
injury application of GKT136901 was ineffective, we re-investigated
the role of NOX4 on neuropathic pain behavior, oxidative stress, and in-
flammatory processes in a different NOX4 KO model and found NOX4
signaling important for the development of neuropathic pain very
early after nerve injury.
2. Material and methods
2.1. Animals
All animal experiments were approved by local state authorities
(Regierung von Unterfranken), comply with the ARRIVE guidelines
and were carried out in accordance with the EU Directive 2010/63/EU
for animal experiments aswell as the German AnimalWelfare Act (Ger-
manMinistry of Agriculture, Health and Economic Cooperation). Exper-
iments were performed on adult male mice at 8–15 weeks of age
weighing 25–35 g. The generation of NOX4-deficient (Nox4−/−) mice
has been described previously (Kleinschnitz et al., 2010). Wild-type
(WT) littermates (Nox4+/+ mice) served as controls. Pharmacological
inhibition of dual NOX1/4 by the NOX4 inhibitor GKT136901
(Vendrov et al., 2010) was performed in 8-week old male C57BL/6
mice (Charles River Laboratories, Research Models and Services
GmbH, Sulzfeld, Germany). Mice were group-housed in boxes in a tem-
perature- and humidity-controlled environment with a 12/12 h light-
dark cycle with standard rodent chow and water ad libitum. The mini-
mal number of animals needed to obtain statistical significance was
used in the present study to reduce animal numbers and to minimize
animal distress. In total, 61 Nox4−/−, 64 Nox4+/+ and 15 C57BL/6 mice
were included in the study. For experimental group planning we ex-
trapolated pain levels from large numbers of own previous experiments
using the CCI pain model, assumed the pain levels of Nox4−/− mice to
50%, and determined the significance level to 0.05 and the power to
0.8 (beta = 0.2).
2.2. Chronic constriction injury (CCI)
CCI was performed according to the original description in rats
(Bennett and Xie, 1988) modified for mice as reported previously
(Schäfers et al., 2003). Surgical procedures were carried out under bar-
biturate anesthesia using sodium pentobarbital (Merial GmbH,Hallbergmoos, Germany) at 50 mg/kg i.p. Briefly, both sciatic nerves
were exposed and three ligatures (7–0 prolene) were placed around
the right sciatic nerve with 1-mm spacing. Ligatures were tightened
until they elicited a brief twitch in the respective hind limb. For sham
surgery, sciatic nerves were exposed in the sameway but without plac-
ing ligatures. Surgeries were performed while being blinded to the ex-
perimental groups.
2.3. Behavioral testing
Behavioral tests were performed on Day−3 and on Day−1 before
CCI to obtain baseline values, and on Days 4, 8, 14, 21, 28, and 35 after
CCI. All behavioral testing was done by the same investigator unaware
of the treatment and the respective genotypes. For all tests, mice were
adapted to the testing environment for at least 1 h before testing.
a) Assessment of tactile allodynia (von Frey hair-induced paw-withdrawal
threshold)
Mice were individually placed on an elevated metallic wire mesh
floor in polyethylene cages. The von Frey filaments (Stoelting Co.,
Wood Dale, USA) were inserted through the mesh floor and applied to
the plantar surface of the hind paw. The force required to bend the
hairs ranged from 0.004 to 28.84 g. Hairs were applied six times each
on the basis of the up-and-down method as described previously
(Chaplan et al., 1994; Geis et al., 2010). The time interval between two
trials was at least 1 min on the same paw and at least 30 s on the alter-
nate paw. A brisk withdrawal of the paw was considered a positive re-
sponse. The 50% withdrawal threshold (i.e. force of the von Frey hair
to which an animal reacts in 50% of the presentations) was recorded.
b) Assessment to thermal hyperalgesia (withdrawal latency to radiant
heat)
The withdrawal latency to heat stimulation was tested using a Plan-
tar Test Instrument (Ugo Basile, Comerio, Italy). The time until the ani-
mals reacted with withdrawal to the stimulation by a radiant heat
source was determined automatically. Each testing period consisted of
a minimum of three presentations for each hind paw. Means of three
tests were calculated and taken for further analysis (Geis et al., 2011).
The time interval between two trials was at least 1 min. All animals
reacted within the 20 s timeframe of the maximal stimulation period.
2.4. Pharmacological NOX inhibition and drug delivery
In a therapeutic approach, we used the small molecule dual NOX1/4
inhibitor GKT136901 (2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-yl-
methyl)-1H-pyrazolo[4.3-c]pyridine-3.6(2H,5H)-dione), which was
dissolved in 0.5% carboxymethyl cellulose, 0.25% polysorbate 20, and
1% dimethyl sulfoxide according to previously published protocols
(Vendrov et al., 2010). GKT136901 has been shown to reduce ROS gen-
eration in vivo when delivered orally in mice (Gaggini et al., 2011;
Teixeira et al., 2016; Vendrov et al., 2010). We therefore administered
GKT136901 (10 mg/kg once daily) through oral gavage using 20-
gauge gavage needles beginning from Day 1 after CCI to Day 21. We
used C57BL/6 mice, which were randomly selected to receive either
GKT136901 or vehicle (i.e. buffer solutionwithout GKT136901). The ex-
perimenter treating the animals was blinded to treatment allocation.
2.5. Euthanasia and tissue processing
After the final testing or at the indicated time points of tissue analy-
sis, micewere deeply anesthetized using sodiumpentobarbital and per-
fused through the left atrium with 20 ml phosphate-buffered saline
(PBS). Bilateral sciatic nerves and L4 and L5 dorsal root ganglia (DRG)
as well as lumbar spinal cord were removed. For immunohistochemis-
try, tissue was then embedded into optimal cutting-temperature com-
pound (TissueTek®, Sakura Finetek Europe B.V., Alphen aan den Rijn,
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gen. For gene expression analysis, native tissue was saved in RNAlater
(QIAGEN GmbH, Hilden, Germany) and immediately stored at −80 °C
for further processing.
2.6. Gene expression analysis
Tissue homogenization, RNA isolation and real-time, quantitative re-
verse transcription polymerase chain reaction (qRT-PCR) were per-
formed as described previously (Göb et al., 2015; Kleinschnitz et al.,
2004). Briefly, total RNA from the ipsilateral sciatic nerve, ipsilateral
pooled L4/L5 DRG, and lumbar spinal cord was prepared from
Nox4−/− mice and control littermates (Nox4+/+) on Days 1, 4, 8, 21,
and 35 after CCI with a Miccra D-8 Homogenizer (ART Prozess- &
Labortechnik GmbH, Müllheim, Germany) using the TRIzol® reagent
(Invitrogen GmbH, Darmstadt, Germany) and was quantified spectro-
photometrically. Then, 250 ng of total RNA were reverse transcribed
with TaqMan® Reverse Transcription Reagents (Applied Biosystems
GmbH, Frankfurt, Germany) according to the manufacturer's protocol
using random hexamers.
Relative gene expression levels of murine NADPH oxidase 2 (Nox2)
(assay ID: Mm01287743_m1, Applied Biosystems), NADPH oxidase 4
(Nox4) (assay ID: Mm00479246_m1, Applied Biosystems), interleukin-
1 beta (Il-1β) (assay ID: Mm 00434228_m1, Applied Biosystems),
tumor necrosis factor-alpha (Tnf-α) (assay ID: Mm 00443258_m1, Ap-
plied Biosystems), and transforming growth factor-beta1 (Tgf-β1) (assay
ID: Mm 00441724_m1, Applied Biosystems) were quantified with fluo-
rescence TaqMan® technology. GAPDH (TaqMan® Pre-Developed
Assay Reagents for Gene Expression, part number: 4352339E, Applied
Biosystems)was used as an endogenous control. The PCRwas performed
with equal amounts of cDNA and water control in the StepOnePlus™
Real-Time PCR System (Applied Biosystems) using the TaqMan® Uni-
versal PCR Master Mix (2 × concentration) (Applied Biosystems). Each
samplewasmeasured in triplicate anddata pointswere examined for in-
tegrity by analysis of the amplification plot. The comparative threshold
cycle method was used for relative quantification of gene expression as
described previously (Livak and Schmittgen, 2001).
2.7. Immunohistochemistry and oxidative chemistry biomarkers
Cryosections (10 μm) of the sciatic nerve from Nox4−/− mice and
control littermates (Nox4+/+) were prepared using a cryostat (Leica
Microsystems GmbH, Wetzlar, Germany). For immunohistochemical
analysis of reactive nitrogen species (RNS), a rabbit polyclonal antibody
to nitrotyrosine (Fisher Scientific GmbH, Schwerte, Germany, EMD
Millipore 06284 Cat. 06-284) was applied at a final dilution of 1:100.
Sections were incubated at room temperature for 2 h, washed three
times for 10 min in 1 × PBS and incubated at room temperature for
45 min with Cy2-conjugated goat anti-rabbit secondary antibody
(1:300, Dianova GmbH, Hamburg, Germany) (Kleinschnitz et al.,
2010). For quantification of nitrotyrosine-positive cells permm2, identi-
cal sections from the sciatic nerve were selected and cell counting was
performed from four subsequent slices (40-μm distance between
slices). The presence of ROSwas visualized on cryosections from the sci-
atic nerves using dihydroethidium (DHE) (D7008, 2 μM stock, Sigma-
Aldrich Chemie GmbH, Munich, Germany Sigma). DHE is a fluorescent
dye that after reaction with ROS is converted into the red fluorescent
compound ethidium, which intercalates into double-stranded DNA. Ox-
idative cell damagewas calculated bymeasuring themean fluorescence
intensity of oxidized ethidium per nerve section from four subsequent
slices (40-μm distance between slices) of Nox4−/− mice or controls
(Nox4+/+). DNA was counterstained using Hoechst reagent (33,342,
Sigma-Aldrich Chemie GmbH). Negative controls included omission of
the primary or secondary antibodies and produced no signal. All sec-
tions were viewed and images were acquired with a Nikon Eclipse 50i
microscope equipped with the DS-U3 DS camera control unit. Imageswere analyzed with NIS-Elements software (Nikon Systems, Tokyo,
Japan).
2.8. Statistical analysis
For statistical analysis SigmaPlot 12.0 (Systat Software GmbH,
Erkrath, Germany) was used. The data were tested for normal distribu-
tion using the Shapiro-Wilk test. Behavioral data was analyzed using a
2-way repeated measures ANOVA and a post-hoc Holm-Sidak pairwise
multiple comparison procedure. Data from the qRT-PCR were analyzed
by 2-way ANOVAwith post-hoc Bonferroni adjustment for P values. For
histological data, an unpaired, 2-tailed Student's t-test was applied. A P
value of b0.05 was considered statistically significant.
3. Results
3.1. Pharmacological NOX4-blockade by GKT136901 is not effective in re-
ducing CCI-induced mechanical allodynia
NOX4 has been reported to contribute to neuropathic pain behavior
in the late phase after peripheral nerve injury (Kallenborn-Gerhardt et
al., 2012). We tested here whether pharmacological NOX4 inhibition
by therapeutic application of the dual NOX1/4 inhibitor GKT136901
(Teixeira et al., 2016; Vendrov et al., 2010) is effective in the CCI
mouse model. GKT136901 was applied from Day1 after CCI in 8-week
old male C57BL/6 mice after random allocation to receive either
GKT136901 or vehicle. Before CCI, both treatment groups had similar
baseline levels of mechanical withdrawal thresholds and heat-induced
withdrawal thresholds. Post-injury treatment with GKT136901 did
not result in improvement of disease signs (Fig.1). After CCI
GKT136901 treatedmice had similarmechanicalwithdrawal thresholds
as control mice throughout the entire experimental period beginning
from Day 4 after CCI (P N 0.05 for Days 4, 8, 14, and 21 after CCI; Fig.
1A). Withdrawal latencies to radiant heat were also not different be-
tween the experimental groups (P N 0.05 for Days 4, 8, 14, and 21
after CCI; Fig. 1B).
3.2. Nox4 is upregulated in the sciatic nerve and DRG after CCI
Since we did not find a reduction of CCI-induced hyperalgesia when
therapeutic NOX4 inhibitionwas started after CCI, we next investigated
the kinetics ofNox4 gene expression in ipsilateral, proximal sciatic nerve
segments, L4/L5 DRG, and lumbar spinal cord fromWTmice after CCI or
sham surgery fromDay 1 to 35 by real-time qRT-PCR analysis.We found
a significant increase in Nox4mRNA after CCI in sciatic nerve on Days 4
(P b 0.05) and 8 (P b 0.01), which later decreased to baseline levels. In
sham-operated mice, Nox4 mRNA was constitutively expressed at low
levels (Fig. 2A). In ipsilateral L4/L5 DRGneurons, we found upregulation
of Nox4mRNA on Day 4 after CCI to levels twofold higher than in sham-
operated controls (P b 0.01; Fig. 2B). In lumbar spinal cord, expression of
Nox4 mRNA was unchanged at any time after CCI (Fig. 2C). These data
suggest a potential role of NOX4 in the local pathological signaling pro-
cesses early after nerve damage.
3.3. Mechanical allodynia after CCI is reduced by NOX4-deficiency
Since Nox4mRNA expression is increased early after CCI we then re-
investigated whether and to which time point NOX4 is involved in the
generation of neuropathic pain after CCI by using another NOX4-defi-
cient mouse model (Kleinschnitz et al., 2010). Therefore, Nox4−/−
mice and Nox4+/+ littermate controls were tested for pain behavior
after CCI. Before CCI, Nox4−/− mice and controls had similar baseline
levels of mechanical withdrawal thresholds and heat-induced with-
drawal thresholds. After CCI, Nox4−/− mice had significantly reduced
mechanical withdrawal thresholds throughout the entire experimental
period beginning from early stages after CCI (P b 0.05 for Days 4, 8, 14,
Fig. 1. Neuropathic pain behavior is unchanged after systemic treatment with the dual NOX1/4 inhibitor GKT136901. Manifestation and time course of mechanical (A) and thermal (B)
hyperalgesia was similar in C57BL/6 wild-type mice treated with GKT136901 and those treated with vehicle (control). Two-way ANOVA followed by a post-hoc Holm-Sidak pairwise
multiple comparison procedure.
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to nearly baseline levels on Day 35 after CCI, whereasNox4+/+mice still
showed markedly reduced withdrawal thresholds (P b 0.01 for Day 35;
Fig. 3A). Withdrawal latencies to radiant heat were not different be-
tween the experimental groups (Fig. 3B). Thus, NOX4 seems to be in-
volved in the early development and maintenance of mechanical
allodynia following CCI.
3.4. CCI-induced expression of NOX2 and proinflammatory cytokine Tnf-α
is reduced in Nox4−/− mice
To further elucidate the mechanisms of reduced pain behavior in
NOX4-deficient animals, we performed a temporal gene expression
profile of NOX2 in the sciatic nerve, ipsilateral DRG, and lumbar spinal
cord in NOX4-deficient mice and control littermates (Nox4+/+) afterFig. 2. NOX4 is upregulated early after CCI in mice. Relative gene expression levels of Nox4 in t
spinal cord (C) of wild-type (WT) (Nox4+/+) mice on Days 1, 4, 8, 21, and 35 after sham ope
the sciatic nerve significantly increased already on Days 4 and 8 and normalized thereafter. I
Day 8. No significant differences in Nox4 expression were observed in the lumbar spinal cord
followed by Bonferroni multiple comparison test compared with the control group (sham-opeCCI and sham surgery. NOX2 is another physiologically relevant NOX
isoform that contributes to neuropathic pain hypersensitivity in mice
(Kallenborn-Gerhardt et al., 2014; Kim et al., 2010). Further we ana-
lyzed prototypic pro- and anti-inflammatory cytokines that are
known to be inflammatory markers in the CCI mouse model and that
are involved in the induction and maintenance of neuropathic pain
(Sommer and Kress, 2004). In Nox4+/+ mice, we found that CCI-in-
duced upregulation of Nox2 expression in the sciatic nerve increased
to a maximum on Days 4 and 8 after CCI that was approximately 20
times the value on Day 1 and returned to basal levels at later stages,
e.g. Day 21 and 37 (P b 0.01 for Day 4; P b 0.001 for Day 8; Fig. 4). In
Nox4−/− mice, Nox2 mRNA levels were only gradually, but not signifi-
cantly increased in the sciatic nerve after CCI compared to sham-treated
animals. Accordingly, direct comparison between Nox4−/− and Nox4+/+
mice of Nox2 transcription levels after CCI revealed a remarkablehe ipsilateral, proximal sciatic nerve segments (A), ipsilateral L4/L5 DRG (B), and lumbar
ration or CCI as determined by qRT-PCR analysis. The relative amount of Nox4 mRNA in
n the DRG, Nox4 mRNA was upregulated after CCI on Day 4 and returned to baseline on
after CCI. N = 4–7 mice per group and time point. *P b 0.05; **P b 0.01; 2-way ANOVA
rated mice).
Fig. 3. Neuropathic pain behavior is reduced in NOX4-deficient mice following CCI. (A) Mechanical withdrawal thresholds (von Frey test on the ipsilateral hind paw) of Nox4+/+ and
Nox4−/− mice are shown before and after CCI. Baseline levels were similar in both groups. After CCI, withdrawal threshold was reduced in both groups. In Nox4−/− mice, the decrease
in withdrawal thresholds was significant throughout the observation period. On Day 35 after CCI, the withdrawal threshold in Nox4−/− mice was close to the baseline value, whereas
in Nox4+/+ mice mechanical hyperalgesia remained prevalent. (B) Thermal hyperalgesia as revealed by sensitivity to radiant heat on a hind paw was unchanged in both experimental
groups. *P b 0.05; **P b 0.01; 2-way ANOVA followed by a post-hoc Holm-Sidak pairwise multiple comparison procedure.
Fig. 4.NOX4-deficiency reduces CCI-induced NOX2 upregulation. Relative gene expression levels of Nox2 in the ipsilateral, proximal sciatic nerve segments (A), ipsilateral L4/L5 DRG (B),
and lumbar spinal cord (C) ofNox4−/− and Nox4+/+mice on Days 1, 4, 8 (Days 21 and 35 not shown) after sham operation or CCI as determined by qRT-PCR analysis. In the sciatic nerve,
Nox2was strongly upregulated inNox4+/+ mice after CCI to a maximumon Days 4 and 8 of about 20 times the value on Day 1. Nox2 gene expression also increased in the sciatic nerve of
Nox4−/−mice after CCI, but was significantly lower as compared to that ofNox4+/+mice after CCI. In the DRG and spinal cord, Nox2mRNA expressionwas verymild after CCI irrespective
of the genotype (Nox4+/+ orNox4−/−) or the time after surgery.N=4–7mice per group and timepoint. *P b 0.05 forNox4+/+ vs.Nox4−/−mice after CCI; ##P b 0.01 forNox4+/+mice after
CCI vs. sham operation; 2-way ANOVA followed by Bonferroni multiple comparison test compared to the respective control group (sham-operated mice or Nox4+/+ mice).
Fig. 5. NOX4-deficiency alleviates CCI-induced early inflammatory reactions in the sciatic nerve and DRG. (A) Relative gene expression levels of Il-1β, Tnf-α, and Tgf-β1 in the ipsilateral,
proximal sciatic nerve segments ofNox4−/− andNox4+/+mice onDays 1, 4, 8, 21, and 35 after sham operation or CCI as determined by qRT-PCR analysis. In ipsilateral sciatic nerve, CCI led
to a robust and early induction of gene expression of proinflammatory Il-1β and Tnf-α in Nox4+/+ and Nox4−/− mice with a maximum on Day 4, which then decreased from Day 8. The
maximal CCI-induced increase in Tnf-α onDay 4was lower inNox4−/−mice compared toNox4+/+mice. Gene expressionof anti-inflammatory Tgf-β1 culminated onDays4 and 8, andwas
significantly enhanced in Nox4−/− mice after CCI compared to sham operated mice. (B) Relative gene expression of Il-1β, Tnf-α, and Tgf-β1 in the ipsilateral DRG L4/L5 of Nox4−/− and
Nox4+/+ mice. CCI-induced increase of the pro- and anti-inflammatory cytokines in ipsilateral DRG occurred later after CCI and was less pronounced than in the sciatic nerve.
Similarly, maximal increase in Tnf-α on Day 4 after CCI was significantly lower in Nox4−/− mice compared to Nox4+/+ mice. Transcription of Tgf-β1 was significantly increased in
Nox4+/+ mice on Day 4 after CCI compared to Nox4−/− mice. On Day 8 after CCI, Tgf-β1 is significantly increased in Nox4−/− mice compared to Nox4+/+ mice. (C) Relative gene
expression of Il-1β, Tnf-α, and Tgf-β1 in the lumbar spinal cord. Pro- and anti-inflammatory cytokines were constitutively expressed at low levels without relevant changes in both CCI
groups. N = 4–7 mice per group and timepoint. *P b 0.05, **P b 0.01 for Nox4+/+ vs. Nox4−/− mice after CCI; #P b 0.05; ##P b 0.01, ###P b 0.001 for Nox4+/+ mice after CCI vs. sham
operation; §P b 0.05, §§P b 0.01 for Nox4−/− mice after CCI vs. sham operation; 2-way ANOVA followed by Bonferroni multiple comparison test compared with the respective control
group (sham-operated mice or Nox4+/+ mice).
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In the DRG or spinal cord we did not observe significant differences be-
tween Nox4−/− and Nox4+/+ mice in the expression of Nox2 mRNA
after CCI or sham operation at any time point (Fig. 4).
Further, CCI led to an early robust increase in mRNA expression of
the proinflammatory cytokines Il-1β and Tnf-α in the injured nerve
with a maximum on Days 1 and 4 after CCI and decreasing from Day
8, compared to the sham-operated control groups (Il-1β: P b 0.05 for
Day 1 and P b 0.01 for Day4; Tnf-α: P b 0.001 for Day4; Fig. 5A). This pat-
tern of upregulation was also present in the DRG but was less pro-
nounced (Tnf-α: P b 0.01 for Day 4; Fig. 5B). Following CCI, the
expression of Il-1β in the sciatic nerve of Nox4−/− mice was not signifi-
cantly different to that of Nox4+/+ mice (Fig. 5A). In contrast, on Day 4
after CCI, the expression of Tnf-α in the sciatic nerve and DRG of
Nox4−/− mice was significantly lower as compared to Nox4+/+ mice
(P b 0.05; Fig. 5A,B). Alongwith themassive increase in proinflammato-
ry cytokines, we also detected an upregulation of the anti-inflammatory
cytokine Tgf-β1 onDays 4 and 8 after CCI in the injured sciatic nerve and
DRG (Fig. 5A,B).While Tgf-β1 transcription levels in the sciatic nerve did
not differ significantly between Nox4+/+ mice subjected to CCI and
sham operation, CCI induced a significant upregulation of anti-inflam-
matory Tgf-β1 in the injured sciatic nerve of NOX4-deficient mice on
Days 4 and 8 (P b 0.01 for Day 4 and P b 0.05 for Day 8; Fig. 5A). In lum-
bar spinal cord, we observed only marginal changes in cytokine expres-
sion irrespective of the genotype or time after CCI (Fig. 5C). Thus, NOX4
signaling may be important in the regulation of early modulatory in-
flammatory processes leading to neuropathic pain development follow-
ing nerve lesion.
3.5. NOX4-deficiency attenuates oxidative and nitrative stress in the le-
sioned sciatic nerve in the acute phase after CCI
NOX4 is responsible for the formation of ROS, i.e. superoxide and hy-
drogen peroxide, which can interact with nitric oxide to form RNS. To
assess the generation and involvement of oxidative and nitrative stress
in early development of neuropathic pain after CCI we stained cross-
sections of sciatic nerves to evaluate deposition of DHE and
nitrotyrosine, two broad-spectrum indicators of oxidative and nitrative
stress (Fig. 6). On Day 1 after CCI, we detected significantly lower
amounts of ROS in the sciatic nerve of Nox4−/− mice compared to
Nox4+/+ mice as quantified by the mean fluorescence intensity of oxi-
dized DHE (P b 0.05; Fig. 6A). Since DHE staining may also be a marker
for oxidative chemistry events in general, e.g. formation of peroxynitrite
and nitration of the amino acid tyrosine, we further analyzed the extent
of protein nitration in Nox4−/− and Nox4+/+ mice on Day 1 after CCI. In
accordance with reduced DHE detection in the injured nerve of NOX4-
deficient mice, we also found significantly reduced nitrotyrosine-posi-
tive cells in these mice compared to Nox4+/+ mice (P b 0.05; Fig. 6B).
4. Discussion
The main finding of the study is that the ROS-producing enzyme
NOX4 is important in the early generation of neuropathic pain following
peripheral nerve lesions in mice by locally generating oxidative stress
products very soon after CCI. Deficiency in NOX4 leads to a reduction
in of local proinflammatory cytokine upregulation and to an attenuation
of mechanical hypersensitivity. Importantly, post-injury pharmacologi-
cal inhibition of NOX4 after the nerve lesion did not result in any im-
provement of disease signs, suggesting that NOX4 activation is crucial
at the initial stages of neuropathic pain development.
NADPH oxidases were identified as key contributors to oxidative
stress and ROS-mediated cell death in pain (Kallenborn-Gerhardt et al.,
2012, 2014; Kimet al., 2010) andother neurological disorders such as ep-
ilepsy (Williams et al., 2015), brain trauma (Ansari et al., 2014) and
stroke (Kleinschnitz et al., 2010). In a spinal nerve transection model
NOX2 was responsible for peripheral injury-induced spinal cordmicroglia activation, ROS formation and subsequent pain hypersensitivi-
ty (Kim et al., 2010). NOX2-deficient mice displayed significantly re-
duced expression levels of the proinflammatory cytokines Il-1β and
Tnf-α, which is in agreement with our observation of a reduced inflam-
matory response in NOX4-deficient mice after peripheral nerve injury.
Interestingly, in the spinal nerve transection model, Nox2 gene expres-
sion was observed not only in dorsal horn neurons but predominantly
in spinal cord microglia dependent on toll-like receptor 2 signaling, and
nuclear factor-κB and p38 mitogen-activated protein kinase regulation
(Kim et al., 2010; Lim et al., 2013). In contrast, the NOX isoforms 1, 3,
and 4 as well as Duox1 and 2, are not expressed in spinal cord microglia
following spinal nerve transection (Kim et al., 2010). NOX1was reported
to hold a central function in the development of inflammatory pain by in-
ducing ROS production inDRGneurons leading to enhanced transient re-
ceptor potential vanilloid 1 activity and increased sensitivity to painful
stimuli (Ibi et al., 2008). In contrast to NOX1, NOX4 was suggested to
contribute to the maintenance of neuropathic pain after peripheral
nerve injury (Kallenborn-Gerhardt et al., 2014; Kim et al., 2010). In a re-
cent study with a different NOX4 KO mouse model as used here
Kallenborn-Gerhardt et al. reported that loss of NOX4 reduced late-
phase neuropathic pain and that tamoxifen-induced deletion of Nox4 in-
duced analgesia in already existing later pain states in the spared nerve
injury (SNI) neuropathic pain mode (Kallenborn-Gerhardt et al., 2012).
Based on these findings we tried to evaluate the therapeutic effect of
the pharmacological NOX1/4 inhibitor GKT136901 after CCI (Teixeira et
al., 2016; Vendrov et al., 2010). Surprisingly, we did not find any effect
of systemic NOX1/4 blockade in behavioral analysis. Therefore, we ana-
lyzed again the extent and the kinetics of NOX4 signaling and found up-
regulation of Nox4 gene expression and formation of ROS and RNS very
early after CCI. Accordingly, neuropathic pain behavior as well as NOX2
expression and ROS and RNS production was significantly reversed in
NOX4 KO mice. Our findings of NOX4 upregulation predominantly at
the lesion site in the peripheral nerve andmuch less in the spinal ganglia
and spinal cord point toward a primary role of NOX4 in direct develop-
ment of neuropathic pain instead of modifying secondary processes of
central sensitization in higher pain processing structures. Additionally,
we identified a reduction of early local proinflammatory cytokine upreg-
ulation as an important beneficial effect of NOX4-deficiency in our CCI
model.We observed a reduced expression of proinflammatory cytokines
Il-1β and Tnf-α, as well as an increased expression of anti-inflammatory
Tgf-β in the sciatic nerves and DRG from Day 1 to 8. The reduction of
local NOX2 expression and protein nitration in the lesioned nerve was
slightlymore pronounced than the downregulation of pro-inflammatory
cytokines and reduction of neuropathic pain behavior. This is explained
as NOX2 signaling and nitrosylation are directly linked to NOX4 deletion
which in turn may then influence local inflammation and finally neuro-
pathic pain behavior. It is well established that increased levels of proin-
flammatory cytokines in the lesioned nerves may change axonal
properties, worsen outcome, and thus strengthen chronic pain condi-
tions (Sommer and Kress, 2004). It has been shown in several experi-
mental studies that the acute response in the lesioned nerve is
associatedwith the development of neuropathic pain. Injection of pro-in-
flammatory cytokines in healthy nerves in equivalent doses to those de-
termined after nerve lesion induce pain behavior (Zelenka et al., 2005)
whereas cytokine inhibitors applied locally to the nerve reduce pain be-
havior (Sommer et al., 2001a, 2001b). Also systemic antagonism of pro-
inflammatory cytokines or administration of anti-inflammatory
cytokines reduces neuropathic hyperalgesia in animal models (Schäfers
and Sommer, 2007). Importantly, these local inflammatory changes are
also observed in humans, e.g. in sural nerve biopsies of patients suffering
from painful neuropathy (Empl et al., 2001; Uceyler et al., 2007, 2015).
We used prolene sutures in this mouse model, which results in sta-
ble neuropathic pain-related behavior and induces local inflammatory
changes as reported previously (Ruscheweyh et al., 2007; Schäfers et
al., 2002). The original CCI model was described using chromic gut su-
tures (Bennett and Xie, 1988). In the past, loose ligatures performed
Fig. 6.NOX4-deficiency reduces the formation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the sciatic nerve in the acute phase after CCI. (A, left) Representative
cross-sections of ipsilateral sciatic nerves from Nox4+/+ and Nox4−/− mice on Day 1 after CCI stained for ROS using dihydroethidium (DHE). (A, right middle) Quantification of oxidized
ethidium revealed significantly lower ROS in the sciatic nerve of Nox4−/− mice on Day 1 after CCI compared to Nox4+/+ mice. (B, left) Representative cross-sections of ipsilateral sciatic
nerves from Nox4+/+ and Nox4−/− mice on Day 1 after CCI stained for RNS using antibodies against α-nitrotyrosine (NTyr). (B, right middle) Quantification of NTyr-positive cells/mm2
revealed significantly reduced RNS in the injured nerves and the perineural tissue of Nox4−/− mice on Day 1 after CCI compared to Nox4+/+ mice. Hoechst stain (blue) was used to
visualize DNA. N = 6–8 mice. *P b 0.05. Scale bar represents 200 μm. AU, arbitrary unit.
101C. Geis et al. / Experimental Neurology 288 (2017) 94–103with simple (non-chromic) gut and with silk, were shown to be less ef-
ficient in inducing pain behavior than chromic gut (Maves et al., 1993).
This discrepancy is most likely caused by the technique of tying theligatures. While we use “loosely constrictive” ligatures that lead to par-
tialWallerian degeneration of the nerve (Sommer et al., 1993, 1995) no
matter which type of ligature is used, others have used very loose
102 C. Geis et al. / Experimental Neurology 288 (2017) 94–103ligatures, not constricting the nerve, or have simply put chromic gut
near the nerve (Maves et al., 1993). In the latter case, a chemical compo-
nent was implied to interact with the nerve and to induce hyperalgesia.
In contrast, if the ligatures are tied in away to induce actual axonal dam-
age, the type of ligature is less important.
Since post-injury inflammation is a key-mediator of neuropathic
pain development and maintenance of the painful condition
(Kleinschnitz et al., 2006; Sommer and Kress, 2004), our data support
the notion that targeting NOX4 may be a promising therapeutic inter-
vention. Indeed, blockingNOX4 function by genetic deletion or pharma-
cological inhibition proves to be effective also in other disease models,
i.e. in models of atherosclerosis (Vendrov et al., 2010), type 2 diabetes
(Sedeek et al., 2013), liver inflammation (Lan et al., 2015), ischemic ret-
inopathy (Deliyanti and Wilkinson-Berka, 2015), and of epithelial cili-
ary dysfunction in neutrophilic asthma (Wan et al., 2016).
Since we describe importance of NOX4 signaling at early stages in
the development of neuropathic pain and others found beneficial effects
of NOX4 deletion in another mouse model in late stages of neuropathic
pain, we now suggest that future studies should aim to define the im-
portance and to evaluate a possible therapeutic window for a pharma-
cological approach of NOX4 inhibition in patients with nerve lesions
and neuropathic pain. This could be achieved by analysis of nerve biop-
sies or surgery material after nerve trauma at different stages after inju-
ry or neuropathic pain development. Thereafter, animal models with
matching time courses of NOX4 regulation, ROS production, cytokine
regulation, and development of neuropathic pain should be explored
for further pharmacological studies.
In principle, oral delivery of GKT136901 at a dose of 10 mg/kg once
daily from Day 1 to 21 may also be inadequate for our CCI model. How-
ever, the dose and timing of application was adapted from previous
studies (Vendrov et al., 2010) that proved to be efficient for systemic
NOX4 inhibition and showed beneficial effects in atherosclerotic mice.
Another theoretical possibility for the ineffectiveness of GKT136901 is
that this dual NOX1/4 inhibitor may generally not be suitable for suc-
cessful treatment of neuropathic pain given that beside NOX1 and 4
also the NOX isoforms 2 is upregulated after pain induction. However,
this is relativized by our observation that CCI-induced Nox2 upregula-
tion is impaired in our NOX4 KO mice. We also cannot exclude that
pain relief in the NOX4 deficient mice is due to reduction in NOX2 sig-
naling. However, as mentioned above and in contrast to our findings
of NOX4 upregulation and cytokine dysregulation in the sciatic nerve,
upregulation of Nox2 gene expression is mainly observed in microglia
of the spinal cord in neuropathic pain models (Kallenborn-Gerhardt et
al., 2014; Kim et al., 2010). Organ- or cell-type specific function is a re-
markable prerequisite of the NOX enzymes, especially of NOX4, which
is suggested to provoke selective ischemia-reperfusion injury primarily
in the brain (Kleinschnitz et al., 2010) and, to a much lesser extent, also
in other organs (Braunersreuther et al., 2013; Wilkinson-Berka et al.,
2014).5. Conclusion
Our study describes NOX4 as a major contributor to the initiation of
neuropathic pain at early stages after nerve lesion. This is accompanied
by a combined induction of inflammatorymediators andoxidative stress
mechanisms. Since holistic NOX4 blockade per se is beneficial but post-
acute NOX inhibition seems to be ineffective in neuropathic pain devel-
opment in this mouse model, future studies should focus on evaluating
the role and time course of NOX4 signaling in neuropathic pain in
humans to identify possibilities for pharmacological intervention.Conflicts of interest
None.Funding
This work was supported by the German Federal Ministry of Educa-
tion and Research (BMBF; Center for Sepsis Control and Care, D3 to CG)
and intramural funds of the University of Würzburg, Germany.Acknowledgements
We thank L. Biko, B. Dekant, and D. Urlaub for expert technical
assistance.References
Altenhöfer, S., Kleikers, P.M., Radermacher, K., Scheurer, P., Rob Hermans, J.J., Schiffers, P.,
Ho, H., Wingler, K., Schmidt, H.H.W., 2012. The NOX toolbox: validating the role of
NADPH oxidases in physiology and disease. Cell. Mol. Life Sci. 69, 2327–2343.
Altenhofer, S., Radermacher, K.A., Kleikers, P.W., Wingler, K., Schmidt, H.H., 2014. Evolu-
tion of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engage-
ment (Antioxid Redox Signal).
Ansari, M.A., Roberts, K.N., Scheff, S.W., 2014. A time course of NADPH-oxidase up-regu-
lation and endothelial nitric oxide synthase activation in the hippocampus following
neurotrauma. Free Radic. Biol. Med. 77, 21–29.
Bennett, G.J., Xie, Y.K., 1988. A peripheral mononeuropathy in rat that produces disorders
of pain sensation like those seen in man. Pain 33, 87–107.
Braunersreuther, V., Montecucco, F., Asrih, M., Pelli, G., Galan, K., Frias, M., Burger, F.,
Quindere, A.L., Montessuit, C., Krause, K.H., Mach, F., Jaquet, V., 2013. Role of
NADPH oxidase isoforms NOX1, NOX2 and NOX4 inmyocardial ischemia/reperfusion
injury. J. Mol. Cell. Cardiol. 64, 99–107.
Chaplan, S.R., Bach, F.W., Pogrel, J.W., Chung, J.M., Yaksh, T.L., 1994. Quantitative assess-
ment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55–63.
Deliyanti, D., Wilkinson-Berka, J.L., 2015. Inhibition of NOX1/4 with GKT137831: a poten-
tial novel treatment to attenuate neuroglial cell inflammation in the retina.
J. Neuroinflammation 12, 136.
Empl, M., Renaud, S., Erne, B., Fuhr, P., Straube, A., Schaeren-Wiemers, N., Steck, A.J., 2001.
TNF-alpha expression in painful and nonpainful neuropathies. Neurology 56,
1371–1377.
Finnerup, N.B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R.H., Gilron, I.,
Haanpaa, M., Hansson, P., Jensen, T.S., Kamerman, P.R., Lund, K., Moore, A., Raja,
S.N., Rice, A.S., Rowbotham, M., Sena, E., Siddall, P., Smith, B.H., Wallace, M., 2015.
Pharmacotherapy for neuropathic pain in adults: a systematic review andmeta-anal-
ysis. Lancet Neurol. 14, 162–173.
Gaggini, F., Laleu, B., Orchard, M., Fioraso-Cartier, L., Cagnon, L., Houngninou-Molango, S.,
Gradia, A., Duboux, G., Merlot, C., Heitz, F., Szyndralewiez, C., Page, P., 2011. Design,
synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine
and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors. Bioorg. Med.
Chem. 19, 6989–6999.
Gavazzi, G., Banfi, B., Deffert, C., Fiette, L., Schappi, M., Herrmann, F., Krause, K.-H., 2006.
Decreased blood pressure in NOX1-deficient mice. FEBS Lett. 580, 497–504.
Geis, C., Graulich, M., Wissmann, A., Hagenacker, T., Thomale, J., Sommer, C., Schafers, M.,
2010. Evoked pain behavior and spinal glia activation is dependent on tumor necrosis
factor receptor 1 and 2 in a mouse model of bone cancer pain. Neuroscience 169,
463–474.
Geis, C., Beyreuther, B.K., Stohr, T., Sommer, C., 2011. Lacosamide has protective disease
modifying properties in experimental vincristine neuropathy. Neuropharmacology
61, 600–607.
Göb, E., Reymann, S., Langhauser, F., Schuhmann, M.K., Kraft, P., Thielmann, I., Göbel, K.,
Brede, M., Homola, G., Solymosi, L., Stoll, G., Geis, C., Meuth, S.G., Nieswandt, B.,
Kleinschnitz, C., 2015. Blocking of plasma kallikrein ameliorates stroke by reducing
thromboinflammation. Ann. Neurol. 77, 784–803.
Ibi, M., Matsuno, K., Shiba, D., Katsuyama, M., Iwata, K., Kakehi, T., Nakagawa, T., Sango, K.,
Shirai, Y., Yokoyama, T., Kaneko, S., Saito, N., Yabe-Nishimura, C., 2008. Reactive oxy-
gen species derived from NOX1/NADPH oxidase enhance inflammatory pain.
J. Neurosci. 28, 9486–9494.
Jaggi, A.S., Singh, N., 2011. Therapeutic targets for themanagement of peripheral nerve in-
jury-induced neuropathic pain. CNS Neurol. Disord. Drug Targets 10, 589–609.
Kallenborn-Gerhardt, W., Schroder, K., Del Turco, D., Lu, R., Kynast, K., Kosowski, J.,
Niederberger, E., Shah, A.M., Brandes, R.P., Geisslinger, G., Schmidtko, A., 2012.
NADPH oxidase-4 maintains neuropathic pain after peripheral nerve injury.
J. Neurosci. 32, 10136–10145.
Kallenborn-Gerhardt, W., Schroder, K., Geisslinger, G., Schmidtko, A., 2013. NOXious sig-
naling in pain processing. Pharmacol. Ther. 137, 309–317.
Kallenborn-Gerhardt, W., Hohmann, S.W., Syhr, K.M., Schroder, K., Sisignano, M., Weigert,
A., Lorenz, J.E., Lu, R., Brune, B., Brandes, R.P., Geisslinger, G., Schmidtko, A., 2014.
Nox2-dependent signaling between macrophages and sensory neurons contributes
to neuropathic pain hypersensitivity. Pain 155, 2161–2170.
Kim, D., You, B., Jo, E.K., Han, S.K., Simon, M.I., Lee, S.J., 2010. NADPH oxidase 2-derived re-
active oxygen species in spinal cord microglia contribute to peripheral nerve injury-
induced neuropathic pain. Proc. Natl. Acad. Sci. U. S. A. 107, 14851–14856.
Kleinschnitz, C., Brinkhoff, J., Zelenka, M., Sommer, C., Stoll, G., 2004. The extent of cyto-
kine induction in peripheral nerve lesions depends on the mode of injury and
NMDA receptor signaling. J. Neuroimmunol. 149, 77–83.
103C. Geis et al. / Experimental Neurology 288 (2017) 94–103Kleinschnitz, C., Hofstetter, H.H., Meuth, S.G., Braeuninger, S., Sommer, C., Stoll, G., 2006. T
cell infiltration after chronic constriction injury of mouse sciatic nerve is associated
with interleukin-17 expression. Exp. Neurol. 200, 480–485.
Kleinschnitz, C., Grund, H., Wingler, K., Armitage, M.E., Jones, E., Mittal, M., Barit, D.,
Schwarz, T., Geis, C., Kraft, P., Barthel, K., Schuhmann, M.K., Herrmann, A.M., Meuth,
S.G., Stoll, G., Meurer, S., Schrewe, A., Becker, L., Gailus-Durner, V., Fuchs, H.,
Klopstock, T., de Angelis, M.H., Jandeleit-Dahm, K., Shah, A.M., Weissmann, N.,
Schmidt, H.H.H.W., 2010. Post-stroke inhibition of induced NADPH oxidase type 4
prevents oxidative stress and neurodegeneration. PLoS Biol. 8, e1000479.
Lam, G.Y., Huang, J., Brumell, J.H., 2010. The many roles of NOX2 NADPH oxidase-derived
ROS in immunity. Semin. Immunopathol. 32, 415–430.
Lan, T., Kisseleva, T., Brenner, D.A., 2015. Deficiency of NOX1 or NOX4 prevents liver in-
flammation and fibrosis in mice through inhibition of hepatic stellate cell activation.
PLoS One 10, e0129743.
Lim, H., Kim, D., Lee, S.J., 2013. Toll-like receptor 2 mediates peripheral nerve injury-in-
duced NADPH oxidase 2 expression in spinal cord microglia. J. Biol. Chem. 288,
7572–7579.
Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25, 402–408.
Maves, T.J., Pechman, P.S., Gebhart, G.F., Meller, S.T., 1993. Possible chemical contribution
from chromic gut sutures produces disorders of pain sensation like those seen in
man. Pain 54, 57–69.
Opitz, N., Drummond, G.R., Selemidis, S., Meurer, S., Schmidt, H.H.H.W., 2007. The ‘A's and
‘O's of NADPH oxidase regulation: a commentary on “Subcellular localization and
function of alternatively spliced Noxo1 isoforms”. Free Radic. Biol. Med. 42, 175–179.
Padi, S.S.V., Kulkarni, S.K., 2008. Minocycline prevents the development of neuropathic
pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms.
Eur. J. Pharmacol. 601, 79–87.
Rotshenker, S., 2011. Wallerian degeneration: the innate-immune response to traumatic
nerve injury. J. Neuroinflammation 8, 109.
Ruscheweyh, R., Forsthuber, L., Schoffnegger, D., Sandkuhler, J., 2007. Modification of clas-
sical neurochemical markers in identified primary afferent neurons with Abeta-,
Adelta-, and C-fibers after chronic constriction injury in mice. J. Comp. Neurol. 502,
325–336.
Salvemini, D., Little, J.W., Doyle, T., Neumann, W.L., 2011. Roles of reactive oxygen and ni-
trogen species in pain. Free Radic. Biol. Med. 51, 951–966.
Schafer, F.Q., Buettner, G.R., 2001. Redox environment of the cell as viewed through the
redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med.
30, 1191–1212.
Schäfers, M., Sommer, C., 2007. Anticytokine therapy in neuropathic pain management.
Expert. Rev. Neurother. 7, 1613–1627.
Schäfers, M., Schmidt, C., Vogel, C., Toyka, K.V., Sommer, C., 2002. Tumor necrosis factor-
alpha (TNF) regulates the expression of ICAM-1 predominantly through TNF receptor
1 after chronic constriction injury of mouse sciatic nerve. Acta Neuropathol. 104,
197–205.
Schäfers, M., Geis, C., Svensson, C.I., Luo, Z.D., Sommer, C., 2003. Selective increase of tu-
mour necrosis factor-alpha in injured and spared myelinated primary afferents
after chronic constrictive injury of rat sciatic nerve. Eur. J. Neurosci. 17, 791–804.
Schwartz, E.S., Lee, I., Chung, K., Chung, J.M., 2008. Oxidative stress in the spinal cord is an
important contributor in capsaicin-induced mechanical secondary hyperalgesia in
mice. Pain 138, 514–524.
Sedeek, M., Gutsol, A., Montezano, A.C., Burger, D., Nguyen Dinh Cat, A., Kennedy, C.R.,
Burns, K.D., Cooper, M.E., Jandeleit-Dahm, K., Page, P., Szyndralewiez, C., Heitz, F.,Hebert, R.L., Touyz, R.M., 2013. Renoprotective effects of a novel Nox1/4 inhibitor in
a mouse model of type 2 diabetes. Clin. Sci. 124, 191–202.
Sommer, C., Kress, M., 2004. Recent findings on how proinflammatory cytokines cause
pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia.
Neurosci. Lett. 361, 184–187.
Sommer, C., Galbraith, J.A., Heckman, H.M., Myers, R.R., 1993. Pathology of experimental
compression neuropathy producing hyperesthesia. J. Neuropathol. Exp. Neurol. 52,
223–233.
Sommer, C., Lalonde, A., Heckman, H.M., Rodriguez, M., Myers, R.R., 1995. Quantitative
neuropathology of a focal nerve injury causing hyperalgesia. J. Neuropathol. Exp.
Neurol. 54, 635–643.
Sommer, C., Lindenlaub, T., Teuteberg, P., Schafers, M., Hartung, T., Toyka, K.V., 2001a.
Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different
mouse models of painful mononeuropathy. Brain Res. 913, 86–89.
Sommer, C., Schafers, M., Marziniak, M., Toyka, K.V., 2001b. Etanercept reduces
hyperalgesia in experimental painful neuropathy. J. Peripher. Nerv. Syst. 6, 67–72.
Steinhubl, S.R., 2008. Why have antioxidants failed in clinical trials? Am. J. Cardiol. 101,
S14–S19.
Suzuki, Y., Hattori, K., Hamanaka, J., Murase, T., Egashira, Y., Mishiro, K., Ishiguro, M.,
Tsuruma, K., Hirose, Y., Tanaka, H., Yoshimura, S., Shimazawa, M., Inagaki, N.,
Nagasawa, H., Iwama, T., Hara, H., 2012. Pharmacological inhibition of TLR4-NOX4
signal protects against neuronal death in transient focal ischemia. Sci. Rep. 2, 28.
Teixeira, G., Szyndralewiez, C., Molango, S., Carnesecchi, S., Heitz, F., Wiesel, P., Wood, J.M.,
2016. Therapeutic potential of NADPH oxidase 1/4 inhibitors. Br. J. Pharmacol. http://
dx.doi.org/10.1111/bph.13532 (Epub ahead of print).
Uceyler, N., Rogausch, J.P., Toyka, K.V., Sommer, C., 2007. Differential expression of cyto-
kines in painful and painless neuropathies. Neurology 69, 42–49.
Uceyler, N., Riediger, N., Kafke, W., Sommer, C., 2015. Differential gene expression of cy-
tokines and neurotrophic factors in nerve and skin of patients with peripheral neu-
ropathies. J. Neurol. 262, 203–212.
Vendrov, A.E., Madamanchi, N.R., Niu, X.L., Molnar, K.C., Runge, M., Szyndralewiez, C.,
Page, P., Runge, M.S., 2010. NADPH oxidases regulate CD44 and hyaluronic acid ex-
pression in thrombin-treated vascular smooth muscle cells and in atherosclerosis.
J. Biol. Chem. 285, 26545–26557.
Wan, W.H., Hollins, F., Haste, L., Woodman, L., Hirst, R.A., Bolton, S., Gomez, E., Sutcliffe, A.,
Desai, D., Chachi, L., Mistry, V., Szyndralewiez, C., Wardlaw, A., Saunders, R.,
O'Callaghan, C., Andrew, P.W., Brightling, C., 2016. NADPH oxidase 4 over-expression
is associated with epithelial ciliary dysfunction in neutrophilic asthma. Chest 149,
1445–1459.
Wilkinson-Berka, J.L., Deliyanti, D., Rana, I., Miller, A.G., Agrotis, A., Armani, R.,
Szyndralewiez, C., Wingler, K., Touyz, R.M., Cooper, M.E., Jandeleit-Dahm, K.A.,
Schmidt, H.H., 2014. NADPH oxidase, NOX1, mediates vascular injury in ischemic ret-
inopathy. Antioxid. Redox Signal. 20, 2726–2740.
Williams, S., Hamil, N., Abramov, A.Y., Walker, M.C., Kovac, S., 2015. Status epilepticus re-
sults in persistent overproduction of reactive oxygen species, inhibition of which is
neuroprotective. Neuroscience 303, 160–165.
Yowtak, J., Wang, J., Kim, H.Y., Lu, Y., Chung, K., Chung, J.M., 2013. Effect of antioxidant
treatment on spinal GABA neurons in a neuropathic pain model in the mouse. Pain
154, 2469–2476.
Zelenka, M., Schafers, M., Sommer, C., 2005. Intraneural injection of interleukin-1beta and
tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs
of neuropathic pain. Pain 116, 257–263.
